Generic Medicine Info
Indications and Dosage
Disorders associated with reduced gastrointestinal motility
Adult: For the management of gastrointestinal symptoms including the feeling of swollen abdomen, early satiety, postprandial fullness, upper abdominal pain or discomfort, nausea and vomiting, anorexia, and heartburn; non-ulcer dyspepsia: 50 mg tid. May reduce dose depending on the patient's age and symptoms.
Conditions when increased gastrointestinal motility may be harmful (e.g. gastrointestinal haemorrhage, mechanical obstruction or perforation).
Special Precautions
Elderly. Pregnancy and lactation.
Adverse Reactions
Significant: May cause cholinergic effects.
Gastrointestinal disorders: Abdominal pain, diarrhoea, salivary hypersecretion.
Investigations: Increased ALT, decreased WBC count.
Nervous system disorders: Dizziness, headache.
Skin and subcutaneous tissue disorders: Rash.
Drug Interactions
May reduce activity with anticholinergic agents.
Description: Itopride is a gastroprokinetic agent. It increases acetylcholine concentrations by antagonising dopamine D2 receptors and inhibiting acetylcholinesterase, thereby promoting gastrointestinal motility.
Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability: 60%. Time to peak plasma concentration: 0.5-0.75 hours.
Distribution: Plasma protein binding: Approx 96%, mainly to albumin.
Metabolism: Extensively metabolised in the liver mainly via flavine monooxygenase enzymes.
Excretion: Via urine. Terminal elimination half-life: Approx 6 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Itopride, CID=3792, (accessed on Jan. 21, 2020)

Store below 30°C. Protect from light and moisture.
MIMS Class
GIT Regulators, Antiflatulents & Anti-Inflammatories
ATC Classification
A03FA07 - itopride ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.
Anon. Itopride. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 14/04/2021.

Buckingham R (ed). Itopride Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 14/04/2021.

Elthon 50 mg Tablets (Abbott Laboratories Ltd.). MIMS Thailand. Accessed 14/04/2021.

Ganaton 50 mg Tablets (Abbott Laboratories [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 14/04/2021.

Progit 50 mg Tablets (PharmEng Technology Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 14/04/2021.

Disclaimer: This information is independently developed by MIMS based on Itopride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in